Shots:

• GENFIT to receive ~$543.32M including $135.83M up front, $31.69M as equity investment, ~$407.50M in regulatory, commercial & sales-based milestone along with royalties of ~20%. Ipsen gets an exclusive license globally to develop, manufacture & commercialize elafibranor, currently in P-III (ELATIVE) trial for PBC
• The agreement combines GENFIT’s expertise & technologies with Ipsen’s capabilities to develop elafibranor for PBC. The collaboration also provides an access to Ipsen for other clinical programs
• GENFIT will be responsible for the P-III ELATIVE trial. Ipsen will lead an additional clinical development, including completion of the ELATIVE trial & global commercialization

Ref: Businesswire | Image: Ipsen